AU2018221557C1 - Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination - Google Patents

Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination Download PDF

Info

Publication number
AU2018221557C1
AU2018221557C1 AU2018221557A AU2018221557A AU2018221557C1 AU 2018221557 C1 AU2018221557 C1 AU 2018221557C1 AU 2018221557 A AU2018221557 A AU 2018221557A AU 2018221557 A AU2018221557 A AU 2018221557A AU 2018221557 C1 AU2018221557 C1 AU 2018221557C1
Authority
AU
Australia
Prior art keywords
ser
thr
val
leu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018221557A
Other languages
English (en)
Other versions
AU2018221557A1 (en
AU2018221557B2 (en
Inventor
Jason Russell DOBSON
Margaret Elise MCLAUGHLIN
Susan MOODY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2018221557A1 publication Critical patent/AU2018221557A1/en
Publication of AU2018221557B2 publication Critical patent/AU2018221557B2/en
Application granted granted Critical
Publication of AU2018221557C1 publication Critical patent/AU2018221557C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2018221557A 2017-02-14 2018-02-12 Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination Ceased AU2018221557C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762458640P 2017-02-14 2017-02-14
US62/458,640 2017-02-14
US201862616682P 2018-01-12 2018-01-12
US62/616,682 2018-01-12
PCT/IB2018/050846 WO2018150312A1 (en) 2017-02-14 2018-02-12 Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination

Publications (3)

Publication Number Publication Date
AU2018221557A1 AU2018221557A1 (en) 2019-08-15
AU2018221557B2 AU2018221557B2 (en) 2021-03-11
AU2018221557C1 true AU2018221557C1 (en) 2021-10-14

Family

ID=61526841

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018221557A Ceased AU2018221557C1 (en) 2017-02-14 2018-02-12 Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination

Country Status (12)

Country Link
US (2) US11406633B2 (enExample)
EP (1) EP3582811B1 (enExample)
JP (3) JP2020506159A (enExample)
KR (2) KR20240007717A (enExample)
CN (2) CN117752784A (enExample)
AU (1) AU2018221557C1 (enExample)
CA (1) CA3051989A1 (enExample)
IL (1) IL268341B2 (enExample)
MX (1) MX2019009630A (enExample)
RU (1) RU2767533C2 (enExample)
TW (1) TWI771372B (enExample)
WO (1) WO2018150312A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2020069439A1 (en) * 2018-09-27 2020-04-02 Musc Foundation For Research Development Pharmaceutical combination for the treatment of cancer
WO2020236078A1 (en) * 2019-05-22 2020-11-26 Agency For Science, Technology And Research Pharmaceutical combination
CN113134090B (zh) * 2021-03-26 2022-05-17 武汉大学中南医院 一种抗肿瘤药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196218A1 (en) * 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions for immunotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US20160303137A1 (en) 2015-04-20 2016-10-20 Indiana University Research And Technology Corporation Dual pi3k and wnt pathway inhibition as a treatment for cancer
CN104767366A (zh) * 2015-04-21 2015-07-08 永济新时速电机电器有限责任公司 辅助变流器和车辆

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196218A1 (en) * 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions for immunotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.NAING ET AL, "A first in human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors", JOURNAL OF CLINICAL ONCOLOGY, (2016-05-20), vol. 34, no. 15 suppl, doi:10.1200/JCO.2016.34.15_suppl.3060 *
anonymous, "A study of LGK974 in patients with malignancies dependent on wnt ligands", (2011-05-10), clinical Trials, URL: https://clinicaltrials.gov/ct2/show/NCT01351103?term=LGK974&rank=1, (2018-05-09) *
F. JANKU ET AL, "Abstract C45: Phase I study of WNT974, a first in class porcupine inhibitor, in advanced solid tumors", MOLECULAR CANCER THERAPEUTICS, (2015-12), vol. 14, no. 12 suppl 2, doi:10.1158/1535-7163.TARG-15-C45 *

Also Published As

Publication number Publication date
JP2022174157A (ja) 2022-11-22
AU2018221557A1 (en) 2019-08-15
MX2019009630A (es) 2019-11-08
EP3582811B1 (en) 2024-07-10
RU2767533C2 (ru) 2022-03-17
US20190365746A1 (en) 2019-12-05
RU2019128843A3 (enExample) 2021-05-17
AU2018221557B2 (en) 2021-03-11
US20230063366A1 (en) 2023-03-02
CN117752784A (zh) 2024-03-26
TWI771372B (zh) 2022-07-21
CN110267682A (zh) 2019-09-20
JP2024133495A (ja) 2024-10-02
KR20190112801A (ko) 2019-10-07
TW201836610A (zh) 2018-10-16
WO2018150312A1 (en) 2018-08-23
IL268341A (en) 2019-09-26
IL268341B2 (en) 2023-06-01
US11406633B2 (en) 2022-08-09
EP3582811A1 (en) 2019-12-25
RU2019128843A (ru) 2021-03-16
KR20240007717A (ko) 2024-01-16
CA3051989A1 (en) 2018-08-23
JP2020506159A (ja) 2020-02-27

Similar Documents

Publication Publication Date Title
AU2018221557C1 (en) Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination
US10561653B2 (en) 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
AU2017279046B2 (en) Therapeutic uses of a c-Raf inhibitor
US11001628B2 (en) Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer
US20180177872A1 (en) Combination of PD-1 antagonist with an EGFR inhibitor
AU2016276706B2 (en) Combination therapy for the treatment of cancer
CN108650886A (zh) 多价和多特异性gitr-结合融合蛋白
US20220306737A1 (en) Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
KR20190107719A (ko) 세리티닙 및 항-pd-1 항체 분자의 조합물에 대한 투여 일정
AU2021260982B2 (en) Dosing regimen for treating a disease modulated by CSF-1R
JP2025527535A (ja) 抗ｃｃｒ８抗体およびその使用
US20240270865A1 (en) Cancer treatment methods using anti-cd73 antibodies
RU2835316C1 (ru) Режим введения доз для лечения заболевания, модулируемого csf-1r
US20250215087A1 (en) Combination therapy of kras inhibitor and treg depleting agent
JP6964113B2 (ja) がんの処置に使用するための５−ブロモ−２，６−ジ−（１ｈ−ピラゾール−１−イル）ピリミジン−４−アミン
HK40011167B (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
HK40011167A (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 JUN 2021

TH Corrigenda

Free format text: IN VOL 35 , NO 29 , PAGE(S) 5913 UNDER THE HEADING AMENDMENTS - APPLICATION FOR AMENDMENTS UNDER THE NAME NOVARTIS AG, PATENT APPLICATION NO. 2018221557 CORRECT THE DATE OF THE STATEMENTS FILED TO 03 JUNE 2021 AND 04 JUNE 2021

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENTS FILED 03 JUN 2021 AND 04 JUN 2021

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired